Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202402201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Sophia DeLuca und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Tissue Engineering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIBIB NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Improved understanding of cardiomyocyte (CM) cell cycle regulation may allow researchers to stimulate pro‐regenerative effects in injured hearts or promote maturation of human stem cell‐derived CMs. Gene therapies, in particular, hold promise to induce controlled proliferation of endogenous or transplanted CMs via transient activation of mitogenic processes. Methods to identify and characterize candidate cardiac mitogens in vitro can accelerate translational efforts and contribute to the understanding of the complex regulatory landscape of CM proliferation and postnatal maturation. In this study, A CRISPR knockout‐based screening strategy using in vitro neonatal rat ventricular myocyte (NRVM) monolayers is established, followed by candidate mitogen validation in mature 3‐D engineered cardiac tissues (ECTs). This screen identified knockout of the purine metabolism enzyme adenosine deaminase (ADA‐KO) as an effective pro‐mitogenic stimulus. RNA‐sequencing of ECTs further reveals increased pentose phosphate pathway (PPP) activity as the primary driver of ADA‐KO‐induced CM cycling. Inhibition of the pathway's rate limiting enzyme, glucose‐6‐phosphate dehydrogenase (G6PD), prevented ADA‐KO induced CM cycling, while increasing PPP activity via G6PD overexpression increased CM cycling. Together, this study demonstrates the development and application of a genetic/tissue engineering platform for in vitro discovery and validation of new candidate mitogens affecting regenerative or maturation states of cardiomyocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
- Department of Cell Biology, Duke University, Durham, NC, 27708, USA.
ORCID-Profile: Sophia DeLuca, Nicholas Strash, Nenad Bursac
Förderung
- NIGMS NIH HHS
- NIBIB NIH HHS
- NHLBI NIH HHS
- School of Medicine, Duke University
- American Heart Association
- National Heart, Lung, and Blood Institute
Zitieren
APA
DeLuca, S., Strash, N., Chen, Y., Patsy, M., Myers, A., Tejeda, L., Broders, S., Miranda, A., Jiang, X., & Bursac, N. (2025). Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402201
Vancouver
DeLuca S, Strash N, Chen Y, Patsy M, Myers A, Tejeda L, et al. Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202402201
BibTeX
@article{DeLuca2025,
author = {DeLuca, Sophia and Strash, Nicholas and Chen, Yifan and Patsy, Marisa and Myers, Ashley and Tejeda, Libertad and Broders, Sarah and Miranda, Amber and Jiang, Xixian and Bursac, Nenad},
title = {Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202402201}
}
EUVIMED